What is NSCLC Phase 2 Poziotinib?

Category: Prescription Drugs


NCT03318939 is a phase 2 is a open-label, multicenter study of the efficacy and the safety/tolerability of poziotinib in subjects with non-small cell lung cancer, locally advanced or metastatic, with EGFR or HER2 exon 20 insertion mutation.

No patients have reported taking NSCLC Phase 2 Poziotinib.
Last updated:
There are no evaluations for NSCLC Phase 2 Poziotinib.